Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7172534 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL38895 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL31150922 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL458017 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL2315458 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL29754090 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL23067650 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL29355171 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL260109 | 0.93 | LMNA (0.48) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL187021 | 0.93 | LMNA (0.48) | LMNAL3MBTL1TDP1PDE4AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250258147-A1 | Radiopharmaceutical Production System and Quality Control System Utilizing High Performance Liquid Chromatography | BEST ABT, INC. (US) | 2025-08-14 | — | — | US | claimed |
| EP-4590346-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| EP-4582080-A1 | DISPENSER FOR MUCOSAL ADMINISTRATION COMPRISING 2-DEOXY-GLUCOSE OR ANALOGUES THEREOF | G.ST Antivirals GmbH (AT) | 2025-07-09 | — | — | EP | claimed |
| US-20250114386-A1 | COMBINATION OF A GLYCOSYLATION INHIBITOR WITH ONE CAR CELL THERAPY FOR TREATING CANCER | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2025-04-10 | — | — | US | claimed |
| WO-2025042868-A1 | COMBINATIONS OF HETEROAROTINOIDS AND GLYCOLYTIC INHIBITORS FOR USE AS CANCER TREATMENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-02-27 | — | — | WO | claimed |
| US-12235250-B2 | Radiopharmaceutical production system and quality control system utilizing high performance liquid chromatography | BEST ABT, INC. (US) | 2025-02-25 | — | — | US | claimed |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2025-01-16 | — | — | US | claimed |
| US-20240316083-A1 | MEDICAMENT FOR PREVENTION OR TREATMENT OF RHINOVIRUS INFECTION | MEDIZINISCHE UNIVERSITAT WIEN (AT) | 2024-09-26 | — | — | US | claimed |
| EP-4433077-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL Business Ltd (GB) | 2024-09-25 | — | — | EP | claimed |
| WO-2024064968-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-03-28 | — | — | WO | claimed |
| WO-1997002046-A2 | SACCHARIDE CONJUGATES | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 1997-01-23 | — | — | WO | claimed |
| EP-0641350-A4 | METHOD FOR MAKING 2-FLUORO-2-DEOXYGLUCOSE. | GEN ELECTRIC (US) | 1995-08-23 | — | — | EP | claimed |
| EP-0641350-A1 | METHOD FOR MAKING 2-FLUORO-2-DEOXYGLUCOSE | GENERAL ELECTRIC COMPANY (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1994021653-A1 | METHOD FOR MAKING 2-FLUORO-2-DEOXYGLUCOSE | GENERAL ELECTRIC COMPANY (US) | 1994-09-29 | — | — | WO | claimed |
| US-5057301-A | MODIFIED CELLULAR SUBSTRATES USED AS LINKERS FOR INCREASED CELL RETENTION OF DIAGNOSTIC AND THERAPEUTIC AGENTS | NEORX CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0221588-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-13 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114386-A1 | COMBINATION OF A GLYCOSYLATION INHIBITOR WITH ONE CAR CELL THERAPY FOR TREATING CANCER | ST6GAL1, ENGASE, MAN2A1 | LMNA 4034/4885L3MBTL1 2426/4885TDP1 1832/4885 |
| US-20240316083-A1 | MEDICAMENT FOR PREVENTION OR TREATMENT OF RHINOVIRUS INFECTION | SORD, MME, DERA | LMNA 3911/4885L3MBTL1 2484/4885TDP1 4535/4885 |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | POLRMT, TK2, GOT2 | LMNA 2348/4885L3MBTL1 518/4885TDP1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.